文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症监护病房脓毒症患者血清钾轨迹与30天死亡风险的关联:一项回顾性队列研究

[Association of serum potassium trajectory with 30-day death risk in patients with sepsis in intensive care unit: a retrospective cohort study].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2025-01-01
一句话结论ICU脓毒症患者中,血清钾从正常范围高水平缓慢上升的轨迹与30天死亡风险显著升高独立相关(校正后HR=3.058)。

该回顾性队列研究纳入贵州医科大学附属医院综合ICU、MICU和EICU于2020年1月至2024年1月收治的342例成人脓毒症患者,要求ICU住院至少5天且连续7天以上有血清钾测量。采用基于组的轨迹模型将血清钾变化分为5组。Kaplan-Meier曲线显示各组30天累积生存率差异有统计学意义(Log-Rank检验χ2=14.696,P=0.005),以从正常范围高水平缓慢上升组最低(39.3%)。多因素Cox回归显示该轨迹组30天死亡风险最高(HR=2.341,95%CI 1.049-5.226,P=0.038),校正性别、年龄、病史、SOFA评分、WBC、PLT、PCT、APTT、PT、血钠和SCr后关联持续(HR=3.058,95%CI 1.249-7.488,P=0.014)。

要点

  • 342例ICU脓毒症患者中,从正常范围高水平缓慢上升组30天累积生存率最低(39.3%),各组间差异有统计学意义(χ2=14.696,P=0.005)。
  • 从正常范围高水平缓慢上升轨迹组30天死亡风险最高,未校正HR=2.341(95%CI 1.049-5.226,P=0.038)。
  • 校正性别、年龄、病史、SOFA评分、WBC、PLT、PCT、APTT、PT、血钠和SCr后,该轨迹组HR=3.058(95%CI 1.249-7.488,P=0.014)。
  • 5种血清钾轨迹组分别为:低水平缓慢上升组42例(12.28%)、正常范围中等水平缓慢上升组127例(37.14%)、正常范围中等水平缓慢下降组118例(34.50%)、高水平缓慢下降组28例(8.19%)、正常范围高水平缓慢上升组27例(7.89%)。
  • 除年龄和APTT外,不同血清钾轨迹组患者其他临床特征差异均无统计学意义。

适用人群与场景

  • 贵州医科大学附属医院综合ICU、MICU和EICU于2020年1月至2024年1月收治的成人脓毒症患者。
  • 纳入条件:ICU住院至少5天,且至少连续7天有血清钾测量。

诊断标准与关键阈值

  • 采用基于组的轨迹模型(GBTM,SAS软件)根据ICU入院后血清钾水平趋势变化分为5组:低水平缓慢上升组、正常范围中等水平缓慢上升组、正常范围中等水平缓慢下降组、高水平缓慢下降组、正常范围高水平缓慢上升组。

研究设计与关键结果

  • 回顾性队列研究,最终纳入342例ICU脓毒症患者,来自综合ICU、MICU和EICU。
  • 血清钾轨迹分组:低水平缓慢上升组42例(12.28%)、正常范围中等水平缓慢上升组127例(37.14%)、正常范围中等水平缓慢下降组118例(34.50%)、高水平缓慢下降组28例(8.19%)、正常范围高水平缓慢上升组27例(7.89%)。
  • 除年龄和APTT差异外,各组其他临床特征差异无统计学意义。
  • Kaplan-Meier生存曲线显示各组30天累积生存率差异有统计学意义(Log-Rank检验χ2=14.696,P=0.005),从正常范围高水平缓慢上升组最低(39.3%)。
  • 多因素Cox回归显示从正常范围高水平缓慢上升组30天死亡风险最高(HR=2.341,95%CI 1.049-5.226,P=0.038);校正性别、年龄、病史、SOFA评分、WBC、PLT、PCT、APTT、PT、血钠和SCr后HR=3.058(95%CI 1.249-7.488,P=0.014)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,与血清钾在正常范围内波动的患者相比,ICU脓毒症患者中血清钾从正常范围高水平缓慢上升的轨迹与30天死亡风险显著升高相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the relationship between the trajectories of serum potassium changes after intensive care unit (ICU) admission and 30-day death risk in patients with sepsis.

METHODS: A retrospective cohort study was conducted, including adult patients with sepsis admitted to the comprehensive ICU, medical intensive care unit (MICU) and emergency intensive care unit (EICU) of Guizhou Medical University Affiliated Hospital from January 2020 to January 2024. The patients who had a minimum of 5 days' hospitalisation in the ICU and who had at least 7 consecutive days of the serum potassium measurements were classified into five trajectories groups according to group-based trajectory modelling (GBTM) using SAS software. This was based on tendency changes in serum potassium levels in patients after admission to the ICU, which was categorized as follows: slowly increased from a low level group, slowly increased from a medium level of normal range group, slowly decreased from a medium level of normal range group, slowly decreased from a high level group, and slowly increased from a high level of normal range group. The patient's gender, age, medical history, and white blood cell count (WBC), platelet count (PLT), procalcitonin (PCT), activated partial thromboplastin time (APTT), prothrombin time (PT), blood sodium, and serum creatinine (SCr) at the time of admission to the ICU were collected. At the same time, the patient's worst sequential organ failure assessment (SOFA) score within 24 hours of admission to the ICU, length of ICU stay, and 30-day outcome were record. The differences in clinical data among different groups of patients were compared. The 30-day cumulative survival rates of the various serum potassium trajectories were plotted using Kaplan-Meier survival curves, the groups were then compared using the Log-Rank test. A multivariate Cox proportional risk regression analysis was developed to evaluate the independent effect of serum potassium trajectory on 30-day death risk.

RESULTS: Finally, 342 ICU sepsis patients were enrolled, of which 42 patients in the slowly increased from a low level group (12.28%), 127 patients in the slowly increased from a medium level of normal range group (37.14%), 118 patients in the slowly decreased from a medium level of normal range group (34.50%), 28 patients in the slowly decreased from a high level group (8.19%), and 27 patients in the slowly increased from a high level of normal range group (7.89%). Except for age and APTT differences, there were no statistically significant differences in other clinical characteristics among the patients in the different serum potassium trajectories groups. Kaplan-Meier survival curves showed that there was statistically significant difference in the 30-day cumulative survival rate among the patients in the different serum potassium trajectories groups (Log-Rank test: χ2 = 14.696, P = 0.005), with the lowest in the slowly increased from a high level of normal range group (39.3%). Multivariate Cox proportional risk regression analysis showed that the patients with the serum potassium trajectory of slowly increased from a high level of normal range had the highest 30-day death risk [hazard ratio (HR) = 2.341, 95% confidence interval (95%CI) was 1.049-5.226, P = 0.038]. This association persisted after adjustment for variables such as gender, age, medical history, SOFA score, WBC, PLT, PCT, APTT, PT, blood sodium, and SCr (HR = 3.058, 95%CI was 1.249-7.488, P = 0.014).

CONCLUSION: Compared with the patients whose serum potassium fluctuated within the normal range, the sepsis patients in the ICU with a serum potassium trajectory that slowly increased from a high level of normal range had a significantly higher 30-day death risk.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Deng S, Huang R, Xia F, et al. [Association of serum potassium trajectory with 30-day death risk in patients with sepsis in intensive care unit: a retrospective cohort study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 40814703. doi:10.3760/cma.j.cn121430-20240726-00635

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。